Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (211-220 of 418) with videos related to

Pageof 42
Sort By:
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
The British Journal of Dermatology|August 17, 2022
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational studyAnusuya Kawsar, Charlotte Edwards, Pooja Patel, et al.
British Journal of Cancer|August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIMKarl D Lewis, James Larkin, Antoni Ribas, et al.
European Urology|July 23, 2014
Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkersSakshi Gulati, Pierre Martinez, Tejal Joshi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJeffrey S Weber, F Stephen Hodi, Jedd D Wolchok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
Pageof 42

Showing results (211-220 of 418) with videos related to

Sort By:
Pageof 42
The Oncologist|May 13, 2017
Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of EncephalitisJames Larkin, Bartosz Chmielowski, Christopher D Lao, et al.
British Journal of Cancer|October 7, 2020
Correlative serum biomarker analyses in the phase 2 trial of lenvatinib-plus-everolimus in patients with metastatic renal cell carcinomaChung-Han Lee, Robert J Motzer, Hilary Glen, et al.
Future Oncology (London, England)|July 30, 2020
Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study designNikhil I Khushalani, Adi Diab, Paolo A Ascierto, et al.
The British Journal of Dermatology|August 17, 2022
Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational studyAnusuya Kawsar, Charlotte Edwards, Pooja Patel, et al.
British Journal of Cancer|August 17, 2019
Impact of depth of response on survival in patients treated with cobimetinib ± vemurafenib: pooled analysis of BRIM-2, BRIM-3, BRIM-7 and coBRIMKarl D Lewis, James Larkin, Antoni Ribas, et al.
European Urology|July 23, 2014
Systematic evaluation of the prognostic impact and intratumour heterogeneity of clear cell renal cell carcinoma biomarkersSakshi Gulati, Pierre Martinez, Tejal Joshi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 10, 2017
Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced MelanomaJeffrey S Weber, F Stephen Hodi, Jedd D Wolchok, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2022
Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor-Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 TrialBrian I Rini, Javid J Moslehi, Marc Bonaca, et al.
ESMO Open|July 17, 2020
Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinomaStefanie Aeppli, Eric Innocents Eboulet, Tim Eisen, et al.
The Oncologist|August 5, 2015
Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic NodesChristian Rothermundt, Alexandra Bailey, Linda Cerbone, et al.
Pageof 42